查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1857407

抗血管内皮生长因子疗法市场按产品类型、治疗领域、给药途径、通路和最终用户划分－2025-2032年全球预测

Anti-vascular Endothelial Growth Factor Therapeutics Market by Product Type, Therapeutic Area, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，抗血管内皮生长因子疗法市场将成长至 187.3 亿美元，复合年增长率为 9.57%。

主要市场统计数据
基准年 2024 90.1亿美元
预计年份：2025年 98.7亿美元
预测年份：2032年 187.3亿美元
复合年增长率 (%) 9.57%

简单介绍抗 VEGF 疗法的发展历程以及影响现代视网膜照护的临床和商业性因素。

抗血管内皮生长因子（VEGF）疗法彻底改变了视网膜疾病的临床治疗，从实验生技药品发展成为治疗威胁视力疾病的标准疗法。这些药物针对血管内皮生长因子通道，减少病理性新生血管形成和血管渗漏，从而稳定或改善许多患者的视力。随着时间的推移，治疗模式已从不频繁且繁琐的治疗转变为以患者为中心的治疗方案，兼顾疗效、安全性和给药便利性。

临床重点、技术进步和商业性压力如何融合，正在重新定义视网膜护理的产品价值和护理服务模式

抗VEGF药物领域正经历着一场变革，这场变革是由临床、技术和商业性力量的融合所驱动的。在临床方面，人们越来越关注如何在不影响长期视觉效果的前提下减轻治疗负担，因此，能够延长给药间隔的药物和剂型备受关注。在技​​术方面，製剂、分子设计和给药装置的逐步创新正在催生新的价值主张，这些价值提案的核心在于稳定性、无菌性和给药效率。

美国近期关税调整对生物眼科治疗产品供应链韧性、筹资策略和分销计划的影响

美国近期关税政策的变化和贸易政策调整，为包括抗VEGF药物在内的生技药品的全球供应链规划和成本结构引入了新的变数。这些政策转变正在影响策略采购决策，促使相关人员重新评估其生产布局、区域供应冗余和供应商多元化，以降低进口成本波动带来的风险。製造商和经销商已采取应对措施，探索陆上包装、本地灌装和包装合作以及替代物流方案，以维持供应的连续性并保障利润率。

将产品属性、适应症、剂型、分销管道和医疗保健环境与策略性采纳槓桿联繫起来的综合細項分析

细分市场层面的动态揭示了价值实现的细微差别，这些差别因产品、适应症、给药途径、分销管道和最终用户环境而异。差异化的产品类型，例如阿柏西普、Bevacizumab单抗、布罗卢西珠单抗和雷珠单抗，会影响临床定位、安全性讨论和采购行为。每种分子的临床特征都会影响治疗流程和支付方的优先排序。治疗领域的细分，例如老龄化黄斑部病变、糖尿病黄斑部水肿、近视性脉络膜新生血管和视网膜静脉阻塞，有助于了解患者群体、给药管道和预期治疗进度，从而影响医疗服务提供者如何选择药物以平衡疗效和临床容量。

美洲、欧洲、中东和非洲以及亚太地区的区域动态和存取因素将影响招募和筹资策略。

美洲、欧洲、中东和非洲以及亚太地区的区域动态受不同的管理体制、医疗服务基础设施和支付方环境的影响。在美洲，支付方的整合谈判和垂直整合的医疗服务提供者体系影响着药物配製和合约策略，而大型三级医疗中心和门诊手术中心网路则决定着治疗能力和病患吞吐量。同时，生物相似药和仿单标示外用药的监管政策的明朗化可能会改变竞争动态和采购方式。

传统製造商、生物技术创新者和服务供应商之间既竞争又合作的动态，决定了产品差异化和市场进入的成功。

该领域的竞争动态源自于大型跨国製药公司、眼科专家和生技创新者共同追求差异化的分子设计和递送平台。同时，新参与企业力求透过延长保质期、提高安全性以及提供基于工具的便利性来脱颖而出。此外，生物相似药和替代生技药品的研发也正在加速推进，迫使现有企业加强对生命週期策略、优化服务模式和实证医学证据的投入，以捍卫其临床地位。

对于製造商和医疗保健提供者而言，为实现持续推广应用，切实可行的策略要务是协调临床证据、配方、供应弹性和支付方参与。

产业领导者应优先考虑整合策略，将临床差异化与营运执行和支付方互动结合。首先，应投资于实证医学证据的生成，透过结合真实的世界测试和随机对照试验数据（重点关注安全性、治疗持久性和以患者为中心的结果），预测支付方提出的问题，并加强价值对话。其次，应优化产品包装选择，使注射器和管瓶的规格与医疗服务提供者的工作流程相匹配，从而缩短给药时间、减少浪费、简化库存管理并减少照护现场中的摩擦。

严谨的多源资讯来源方法，结合文献综述、相关人员访谈、细分市场分析和情境检验，确保获得可操作的洞见。

本分析的调查方法结合了来自多个资讯来源的检验综合和结构化的同行评审，以确保其严谨性和有效性。此方法首先对同行评审的临床文献、监管文件、安全资讯和公共更新进行全面审查，以建立关于治疗概况、安全考量和监管背景的事实基础。随后，研究人员对包括视网膜专家、药房主任、医院采购负责人、契约製造和分销合作伙伴在内的相关人员进行了定性访谈，以了解其营运实践和策略重点。

策略要务综合分析强调了整合产品创新、营运、证据产生和协作获取模式的必要性

整体而言，抗VEGF治疗领域正处于一个策略曲折点，临床预期、医疗服务创新和商业性现实正在融合，重塑医疗服务模式。持续的竞争优势可能来自于将分子和器械层面的差异化与操作简便性、强大的循证医学项目以及稳健的供应链相结合的能力。医疗服务提供者和支付方将越来越重视已证实的患者获益与治疗营运成本之间的平衡，从而凸显便捷的给药方式、清晰的安全性以及可靠的供应的重要性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 专利到期和成本压力推动生物相似药的广泛应用
  • 整合人工智慧主导的影像工具以优化个人化VEGF疗法
  • 一种新型玻璃体内给药系统可提供缓释性，以提高患者依从性。
  • 正在进行的临床试验旨在探索靶向 VEGF 和血管生成素通道的新型双特异性抗体
  • 由于糖尿病视网膜病变发生率上升和筛检力度加大，新兴国家市场正在扩张。
  • 生技新兴企业与知名製药公司进行策略合作，开发下一代抗VEGF疗法
  • 监管机构对长期生技药品的免疫抗原性问题加强了审查
  • 成本效益分析驱动高成本生技药品的支付方谈判与报销框架
  • 开发口服小分子 VEGF 抑制剂，旨在减少注射相关併发症
  • 采用远距眼科平台以促进对VEGF抗治疗效果的远距监测

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的抗血管内皮生长因子疗法市场

  • 阿柏西普
  • Bevacizumab
  • 布罗卢西珠单抗
  • 雷珠单抗

9. 依治疗领域分類的抗血管内皮生长因子疗法市场

  • 老龄化黄斑部病变
  • 糖尿病黄斑部水肿
  • 近视性脉络膜新生血管
  • 视网膜静脉阻塞

10. 依给药途径分類的抗血管内皮生长因子疗法市场

  • 玻璃体内注射
    • 预填充式注射器
      • 多剂量预填充
      • 单剂量预填充
    • 管瓶
      • 多剂量管瓶
      • 单剂量管瓶
  • 结膜下注射

第十一章 抗血管内皮生长因子疗法市场（依分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十二章 依最终用户分類的抗血管内皮生长因子疗法市场

  • 门诊手术中心
  • 医院
  • 眼科诊所
  • 专科诊所

13. 抗血管内皮生长因子疗法市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 抗血管内皮生长因子疗法市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国抗血管内皮生长因子疗法市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche Ltd
    • Regeneron Pharmaceuticals, Inc.
    • Bayer AG
    • Novartis AG
    • Eli Lilly and Company
    • Sanofi SA
    • Amgen Inc.
    • Pfizer Inc.
    • Viatris Inc.
    • Samsung Bioepis Co., Ltd
Product Code: MRR-B168537775F5

The Anti-vascular Endothelial Growth Factor Therapeutics Market is projected to grow by USD 18.73 billion at a CAGR of 9.57% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 9.01 billion
Estimated Year [2025] USD 9.87 billion
Forecast Year [2032] USD 18.73 billion
CAGR (%) 9.57%

Concise orientation to the evolution of anti-VEGF therapeutics and the interconnected clinical and commercial forces shaping contemporary retinal care

Anti-VEGF therapeutics have transformed the clinical management of retinal diseases, evolving from experimental biologics into foundational standards of care for conditions that threaten vision. These agents target vascular endothelial growth factor pathways to reduce pathological neovascularization and vascular leakage, thereby stabilizing or improving visual acuity for many patients. Over time, treatment paradigms have shifted from infrequent, high-burden interventions toward more patient-centric regimens that balance efficacy, safety, and dosing convenience.

Current clinical practice emphasizes personalized treatment strategies that consider lesion characteristics, disease chronicity, patient comorbidities, and adherence constraints. Advances in drug formulation and delivery platforms have introduced variations in presentation and administration that materially affect clinic workflows and procurement decisions. Concurrently, heightened scrutiny around safety signals, comparative outcomes, and value-based reimbursement is prompting manufacturers and providers to adopt more transparent evidence generation and risk-mitigation approaches.

This introduction frames the subsequent analysis by focusing on how product attributes, therapeutic indications, administration routes, distribution systems, and end-user dynamics interact to shape commercial and clinical outcomes. It also sets expectations for strategic priorities, including differentiation through dosing frequency, device format innovation, real-world evidence generation, and collaborative models between manufacturers and care providers to improve patient access and treatment continuity.

How converging clinical priorities, technological advances, and commercial pressures are redefining product value and care delivery in retinal therapeutics

The anti-VEGF landscape is undergoing transformative shifts driven by a convergence of clinical, technological, and commercial forces. Clinically, there is an intensified focus on reducing treatment burden without compromising long-term visual outcomes, which is propelling interest in agents and delivery formats that permit extended dosing intervals. Technologically, incremental innovations in formulation, molecular design, and delivery devices are enabling new value propositions centered on stability, sterility, and administration efficiency.

Commercially, payers and health systems increasingly demand robust comparative effectiveness and real-world safety data, prompting manufacturers to invest in longitudinal registries and pragmatic studies. Regulatory pathways are also evolving to address biosimilar entrants and alternative therapeutic modalities, which increases competitive pressure and encourages strategic alliances and licensing deals. In parallel, provider networks are optimizing care delivery through ambulatory surgical centers, integrated ophthalmic clinics, and specialty pharmacies that can streamline patient pathways and inventory management.

Together, these shifts are reshaping how stakeholders prioritize product attributes, contract structures, and collaboration models. Manufacturers that align molecule properties with clinician workflows, invest in post-approval evidence generation, and design flexible commercial channels will be better positioned to capture clinical momentum and sustain adoption amid intensifying competition.

Implications of recent United States tariff adjustments on supply chain resilience, sourcing strategies, and distribution planning for biologic ocular therapies

Recent tariff developments and trade policy adjustments in the United States have introduced additional variables into global supply chain planning and cost structures for biologic therapies, including anti-VEGF agents. These policy shifts have influenced strategic sourcing decisions, encouraging stakeholders to re-evaluate manufacturing footprints, regional supply redundancy, and supplier diversification to mitigate exposure to import-related cost fluctuations. Manufacturers and distributors have responded by considering onshore packaging, local fill-finish partnerships, and alternative logistics arrangements to preserve supply continuity and protect margin integrity.

For providers and pharmacies, the indirect effects of tariff-related adjustments appear in procurement negotiations, inventory strategies, and contracting terms. Procurement teams are strengthening vendor agreements to include clauses that address unexpected tariff fluctuations and are increasing collaboration with specialty distributors to align delivery schedules with clinical demand. Meanwhile, contract manufacturers and component suppliers have accelerated dialogue around qualification of secondary sources for vials, syringes, and single-use devices to reduce bottlenecks that can be exacerbated by import constraints.

Overall, these trade policy dynamics underscore the importance of supply chain resilience planning as an operational imperative. Stakeholders who proactively map their supplier ecosystems, stress-test distribution contingencies, and embed tariff sensitivity into pricing and contracting models will be better prepared to maintain access and operational stability in an uncertain trade environment.

Integrated segmentation analysis linking product attributes, indications, administration formats, distribution pathways, and care settings to strategic adoption levers

Segment-level dynamics reveal nuanced pathways to value that differ by product, indication, administration route, distribution channel, and end-user setting. Product type distinctions among aflibercept, bevacizumab, brolucizumab, and ranibizumab drive clinical positioning, safety conversations, and procurement behavior; each molecule's clinical profile informs where it will be prioritized within treatment algorithms and by payers. Therapeutic area segmentation across age related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, and retinal vein occlusion clarifies patient populations, referral pathways, and expected treatment cadence, influencing how providers select agents to balance efficacy and clinic capacity.

Route-of-administration choices shape device and workflow requirements; intravitreal injection remains the primary delivery mechanism with practical sub-segmentation into prefilled syringe and vial formats. Prefilled syringe options further divide into multi-dose prefilled and single dose prefilled presentations, while vial presentations split into multi-dose vial and single dose vial formats, each combination carrying distinct sterility, handling, and inventory implications. Subconjunctival injection represents a smaller but strategically important alternative that may be relevant for specific delivery innovations or clinical scenarios. Distribution channel distinctions among hospital pharmacies, online pharmacies, and retail pharmacies affect stocking strategies, delivery lead times, and reimbursement interactions. End-user segmentation encompassing ambulatory surgical centers, hospitals, ophthalmic clinics, and specialty clinics highlights variation in administration capacity, staffing competencies, and purchasing arrangements, which in turn informs targeted commercial engagement approaches.

Taken together, these segmentation layers create a multidimensional decision matrix for manufacturers and providers. Effective strategies will integrate product-level differentiation with tailored distribution models and end-user support programs to optimize adoption across clinical settings while addressing operational constraints related to dosing format and administration logistics.

Regional dynamics and access considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific that shape adoption and procurement strategies

Regional dynamics are shaped by distinct regulatory regimes, care delivery infrastructures, and payer environments across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, consolidated payer negotiations and vertically integrated provider systems influence formulary placement and contracting strategies, while large tertiary centers and ambulatory surgical networks shape treatment capacity and patient throughput. Meanwhile, regulatory clarity around biosimilars and off-label use can alter competitive dynamics and procurement practices.

In Europe, Middle East & Africa, reimbursement heterogeneity and regional procurement mechanisms create differentiated pathways to market access; national health technology assessment processes and centralized tendering in some countries emphasize cost-effectiveness and comparative evidence. Provider density and the distribution of specialty clinics versus hospital-based ophthalmology services further modulate treatment accessibility. The Asia-Pacific region presents diverse market archetypes ranging from well-equipped urban centers to under-resourced rural settings, with rapid adoption in high-volume urban clinics and an increasing focus on scalable care models and local manufacturing partnerships to improve access.

Across all regions, supply chain robustness, regulatory harmonization efforts, and local clinician practice patterns will determine the pace and shape of therapeutic uptake. Stakeholders must therefore adopt regionally nuanced engagement plans that align clinical value propositions with reimbursement pathways and infrastructure realities to effectively expand access and sustain long-term adoption.

Competitive and collaborative dynamics among legacy manufacturers, biotech innovators, and service providers that define product differentiation and go-to-market success

Competitive dynamics in the space are driven by a mix of large multinational pharmaceutical companies, specialized ophthalmology companies, and biotech innovators pursuing differentiated molecular designs and delivery platforms. Legacy molecules retain a strong clinical foothold due to extensive real-world experience and established provider familiarity, while newer entrants attempt to differentiate through extended-duration efficacy, improved safety profiles, or device-enabled convenience. Concurrently, development of biosimilar and alternative biologic constructs has intensified, prompting established players to invest in lifecycle strategies, enhanced service models, and evidence generation to defend clinical position.

Partnerships and strategic alliances are increasingly common as companies seek to combine clinical development strengths with commercial reach and manufacturing capacity. Contract manufacturing organizations and specialized fill-finish partners are critical nodes in the supply chain, especially for complex biologics where sterility and cold chain integrity determine product viability. Additionally, collaboration with specialty distributors and pharmacy partners supports more efficient deployment into ambulatory surgical centers and specialty clinics, where most intravitreal administrations occur.

Investor attention and R&D investment continue to flow into formulation improvements, device innovation, and combination approaches that could alter the therapeutic calculus. Companies that align product innovation with pragmatic commercialization models, robust safety monitoring, and clinician engagement will hold an advantage in a market where clinical differentiation must be coupled with operational feasibility to achieve sustained uptake.

Practical strategic imperatives for manufacturers and providers to align clinical evidence, formats, supply resilience, and payer engagement for sustained adoption

Industry leaders should prioritize integrated strategies that align clinical differentiation with operational execution and payer engagement. First, invest in evidence generation that anticipates payer questions by combining randomized data with pragmatic real-world studies focused on safety profiles, treatment durability, and patient-centered outcomes to strengthen value conversations. Second, optimize product presentation choices by aligning syringe and vial formats with provider workflows to reduce administration time, minimize wastage, and simplify inventory management, thereby lowering friction at the point of care.

Third, build supply chain resilience through diversified sourcing, regional manufacturing partnerships, and contingency plans that account for regulatory and trade policy variability. Fourth, develop targeted distribution and contracting strategies tailored to ambulatory surgical centers, hospitals, ophthalmic clinics, and specialty clinics, recognizing that each end-user type has unique procurement cycles and clinical staffing patterns. Fifth, engage early with payers and health system formulary committees to position therapeutic value within clinical pathways and to explore outcomes-based contracting or risk-sharing arrangements where appropriate. Finally, foster collaborative clinical education programs that support safe administration practices and adherence, and leverage digital tools to improve scheduling, patient reminders, and longitudinal outcomes tracking to enhance persistence and clinic efficiency.

Rigorous, multi-source research approach combining literature synthesis, stakeholder interviews, segmentation mapping, and scenario validation to ensure actionable insights

The research methodology underpinning this analysis combined multi-source evidence synthesis with structured expert validation to ensure rigor and relevance. The approach began with a comprehensive review of peer-reviewed clinical literature, regulatory filings, safety communications, and public policy updates to establish a factual base for therapeutic profiles, safety considerations, and regulatory context. Next, qualitative interviews were conducted with a cross-section of stakeholders including retinal specialists, pharmacy directors, hospital procurement leaders, contract manufacturers, and distribution partners to surface operational realities and strategic priorities.

Data triangulation techniques were applied to reconcile divergent inputs and to contextualize claims made in isolated sources. Segmentation mapping was used to align product attributes with therapeutic indications, administration formats, distribution channels, and end-user capabilities, facilitating a multi-dimensional view of adoption drivers. Supply chain and trade policy implications were assessed through scenario analysis to identify vulnerabilities and mitigation levers. Finally, findings were synthesized into actionable recommendations and validated through follow-up consultations with clinical and commercial experts to ensure the practical applicability of the insights presented.

Synthesis of strategic imperatives emphasizing the need to integrate product innovation, operational feasibility, evidence generation, and collaborative access models

In aggregate, the anti-VEGF therapeutic area is at a strategic inflection point where clinical expectations, delivery innovations, and commercial realities converge to reshape care delivery. Sustained competitive advantage will derive from the ability to marry molecular and device-level differentiation with operational simplicity, robust evidence programs, and resilient supply chains. Providers and payers will increasingly demand alignment between demonstrated patient benefit and the operational cost of delivering therapy, which elevates the importance of dosing convenience, safety clarity, and reliable availability.

As stakeholders navigate this environment, collaboration across manufacturers, providers, distributors, and payers will become more central to improving access and optimizing outcomes. Successful strategies will balance near-term operational improvements, such as format alignment and workflow integration, with longer-term investments in evidence generation and partnership models that share risk and reward. Ultimately, the capacity to translate scientific promise into consistent real-world benefit will determine which organizations lead the next phase of retinal therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of biosimilars driven by patent expirations and cost pressures
  • 5.2. Integration of AI-driven diagnostic imaging tools to optimize VEGF therapy personalization
  • 5.3. Emerging intravitreal delivery systems offering sustained release for improved patient compliance
  • 5.4. Ongoing clinical trials exploring novel bispecific antibodies targeting VEGF and angiopoietin pathways
  • 5.5. Market expansion in emerging economies fueled by increasing diabetic retinopathy prevalence and screening initiatives
  • 5.6. Strategic partnerships between biotech startups and established pharma for next-generation anti-VEGF therapies
  • 5.7. Regulatory scrutiny intensifying around immunogenicity concerns with long-term biologic administration
  • 5.8. Cost-benefit analyses driving payer negotiations and reimbursement frameworks for expensive biologics
  • 5.9. Development of oral small-molecule VEGF inhibitors aimed at reducing injection-related complications
  • 5.10. Adoption of teleophthalmology platforms to facilitate remote monitoring of anti-VEGF treatment outcomes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Product Type

  • 8.1. Aflibercept
  • 8.2. Bevacizumab
  • 8.3. Brolucizumab
  • 8.4. Ranibizumab

9. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Therapeutic Area

  • 9.1. Age Related Macular Degeneration
  • 9.2. Diabetic Macular Edema
  • 9.3. Myopic Choroidal Neovascularization
  • 9.4. Retinal Vein Occlusion

10. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Route Of Administration

  • 10.1. Intravitreal Injection
    • 10.1.1. Prefilled Syringe
      • 10.1.1.1. Multi Dose Prefilled
      • 10.1.1.2. Single Dose Prefilled
    • 10.1.2. Vial
      • 10.1.2.1. Multi Dose Vial
      • 10.1.2.2. Single Dose Vial
  • 10.2. Subconjunctival Injection

11. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Anti-vascular Endothelial Growth Factor Therapeutics Market, by End User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Hospitals
  • 12.3. Ophthalmic Clinics
  • 12.4. Specialty Clinics

13. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Anti-vascular Endothelial Growth Factor Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. Regeneron Pharmaceuticals, Inc.
    • 16.3.3. Bayer AG
    • 16.3.4. Novartis AG
    • 16.3.5. Eli Lilly and Company
    • 16.3.6. Sanofi S.A.
    • 16.3.7. Amgen Inc.
    • 16.3.8. Pfizer Inc.
    • 16.3.9. Viatris Inc.
    • 16.3.10. Samsung Bioepis Co., Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AFLIBERCEPT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AFLIBERCEPT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AFLIBERCEPT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BEVACIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BROLUCIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BROLUCIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY BROLUCIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RANIBIZUMAB, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RANIBIZUMAB, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RANIBIZUMAB, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AGE RELATED MACULAR DEGENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MYOPIC CHOROIDAL NEOVASCULARIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MYOPIC CHOROIDAL NEOVASCULARIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MYOPIC CHOROIDAL NEOVASCULARIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MYOPIC CHOROIDAL NEOVASCULARIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MYOPIC CHOROIDAL NEOVASCULARIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MYOPIC CHOROIDAL NEOVASCULARIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE PREFILLED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE PREFILLED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE PREFILLED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE PREFILLED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE PREFILLED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE PREFILLED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE PREFILLED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE PREFILLED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE PREFILLED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE PREFILLED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE PREFILLED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE PREFILLED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE VIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE VIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE VIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE VIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE VIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY MULTI DOSE VIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE VIAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE VIAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE VIAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SINGLE DOSE VIAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBCONJUNCTIVAL INJECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBCONJUNCTIVAL INJECTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBCONJUNCTIVAL INJECTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBCONJUNCTIVAL INJECTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBCONJUNCTIVAL INJECTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBCONJUNCTIVAL INJECTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY OPHTHALMIC CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY OPHTHALMIC CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY OPHTHALMIC CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY OPHTHALMIC CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY OPHTHALMIC CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
  • TABLE 192. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2025-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
  • TABLE 210. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2025-2032 (USD MILLION)
  • TABLE 211. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. LATIN AMERICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY INTRAVITREAL INJECTION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PREFILLED SYRINGE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY VIAL, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREA,